Edition:
United States

Celldex Therapeutics Inc (CLDX.OQ)

CLDX.OQ on NASDAQ Stock Exchange Global Select Market

3.26USD
23 Feb 2017
Change (% chg)

$-0.01 (-0.31%)
Prev Close
$3.27
Open
$3.31
Day's High
$3.36
Day's Low
$3.26
Volume
163,957
Avg. Vol
477,788
52-wk High
$8.73
52-wk Low
$2.86

CLDX.OQ

Chart for CLDX.OQ

About

Celldex Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of several immunotherapy technologies for the treatment of cancer and other diseases. Its lead drug Rintega (also referred to as rindopepimut and CDX-110) is a therapeutic vaccine, which is meant for the... (more)

Overall

Beta: 2.79
Market Cap(Mil.): $399.85
Shares Outstanding(Mil.): 122.28
Dividend: --
Yield (%): --

Financials

  CLDX.OQ Industry Sector
P/E (TTM): -- 46.85 29.68
EPS (TTM): -1.30 -- --
ROI: -45.85 -3.61 13.06
ROE: -48.12 5.27 14.19

BRIEF-COLUMBIA WANGER ASSET MANAGEMENT LLC REPORTS 5.1 PCT PASSIVE STAKE IN CELLDEX THERAPEUTICS AS OF DEC 31, 2016

* COLUMBIA WANGER ASSET MANAGEMENT LLC REPORTS A 5.1 PERCENT PASSIVE STAKE IN CELLDEX THERAPEUTICS INC AS OF DEC 31, 2016 - SEC FILING Source text (http://bit.ly/2lwtvZF) Further company coverage:

Feb 10 2017

BRIEF-Celldex Therapeutics files for offering of up to 18.4 mln shares of common stock

* Files for offering of up to 18.4 million shares of common stock by the selling stockholders Source text : (http://bit.ly/2kpoaTY) Further company coverage:

Jan 26 2017

BRIEF-Celldex reports Q3 loss per share $0.29

* Q3 earnings per share view $-0.33 -- Thomson Reuters I/B/E/S Source text for Eikon: Further company coverage:

Nov 07 2016

BRIEF-Celldex updates on acquisition of Kolltan Pharmaceuticals

* Will acquire Kolltan in a stock-for-stock transaction, in which upfront payment represents an equity value of approximately $62.5 million

Nov 01 2016

More From Around the Web

Earnings vs. Estimates